| Name | Title | Contact Details |
|---|
Were leading a fundamental rethinking of how diabetic limb complications are detected and monitored: noninvasive, mobile & point-of-care. Techstars backed!
AllerVie Health is a national network of board-certified allergists and immunologists partnering together for the advancement of patient care, serving patients across 12 states in 76 clinic locations. Our providers are committed to establishing the allergy and immunology gold standard, expanding access to best-in-class care, and bringing relief and renewed vitality to the millions of Americans affected annually, many of whom live in underserved communities today. AllerVie is relentlessly dedicated to clinical excellence, creating an improved patient experience, and supporting the development of advanced allergy and immunology-focused therapeutics and treatment options. With AllerVie Health, our patients can feel their best, reclaim their lives, and live in freedom!
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
DIGITAL HEALTH. UNLOCKED. Join the journey to transform the worlds health. Healthcare is in the middle of a digital revolution, yet the digital health market is unregulated. As the global leader in providing access to trusted digital health technologi...
Solera is changing lives by guiding people to better health solutions that work. Solera`s value-based technology platform enables successful interventions that address the most prevalent and costly chronic conditions. Solera matches consumers to their best-fit solution within carefully curated networks of digital and community-based point solutions and drives superior engagement and outcomes by managing performance. Solera`s technology platform serves payers and employers by streamlining, integrating, and creating accountability in the point solution ecosystem.